Twin Peaks Wealth Advisors’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio SXTP Stock Details SXTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14	Buy	+8	New	+$23	﹤0.01%	2357

Other funds holding SXTP

KCM

Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Twin Peaks Wealth Advisors's SXTP Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in 60 Degrees Pharmaceuticals (SXTP) in Q1 2026: 8 shares worth $14. The stake represents ﹤0.01% of the portfolio and ranks #2357 among its holdings.

8 funds tracked by Wall St. Rank hold SXTP as of Q1 2026.

Twin Peaks Wealth Advisors held 8 shares of 60 Degrees Pharmaceuticals worth $14 as of Q1 2026.
60 Degrees Pharmaceuticals was a new Twin Peaks Wealth Advisors position in Q1 2026.
60 Degrees Pharmaceuticals made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2357 holding.
8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.